The future of the long-acting beta-adrenergic bronchodilators in the treatment of asthma

Allergy and Asthma Proceedings

Volumn 29, Issue 2, 2008, Pages 103-108

  Mansfield, Lyndon E ^a,b  

^a Texas Tech Health Sciences Center   (United States)

^b Western Sky Medical Research   (United States)

Author keywords

Asthma mortality; Fatal asthma; Formoterol; Long acting agonist; Patient adherence; Safety; Salmeterol; Subsensitivity; Tachyphylaxis; Tolerance

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID;

ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONFERENCE PAPER; DRUG COMBINATION; HUMAN; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; METABOLISM; PATIENT COMPLIANCE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; META-ANALYSIS AS TOPIC; PATIENT COMPLIANCE; RECEPTORS, ADRENERGIC, BETA-2;

EID: 43149087111     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2008.29.3088     Document Type: Conference Paper

References (42)

1. Ernst P, and Ducharme MA. Safety and effectiveness of long acting inhaled β-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 145:692-694, 2006.
2. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 306:1034-1037, 1993.
3. Nelson H, Weiss S, Bleeker E, et al. The Salmeterol Multicenter Asthma Research Trial, a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129:15-26, 2006.
4. Lang DM, and Davis RS. The long acting beta-agonist controversy: A clinical dilemma. Allergy Asthma Proc 28:136-144, 2007.
5. Nelson HS. Is there a problem with inhaleed long-Acting beta adrenergic agonists? J Allergy Clin Immunnol 117:3-16, 2006.
6. Nelson HS. Long-acting beta-agonists in adult asthma: Evidence that these drugs are safe. Prim Care Respir J 15:271-277, 2006.
7. U.S. Department of Health and Human Service. Guidelines for the Diagnosis and Management of Asthma. Public Health Service. Expert Panel Report 2, NIH Publication No. 97-4051, National Institutes of Health National Heart, Lung, and Blood Institute, Bethesda, MD, 1997.
8. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: Effect of long acting β- agonists on severe asthma exacerbations and asthma related deaths. Ann Intern Med 144:904-912, 2005.
9. Churchill VM. General principles for systematic reviews and meta-analysis and a critique of a recent systematic review of long acting β-agonists. J Allergy Clin Immunol 119:303-306, 2007.
10. National Vital Statistics Report. Deaths final data for 2004 Nov 2006. Available online at www.cdc.gov; last accessed May 29, 2007.
11. Repsher LH, Anderson JA, Bush RK, et al. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol. Chest 85:34-38, 1984.
12. Mutlu GM, Moonjelly E, Chan L, et al. Laryngospasm and paradoxical bronchoconstriction after repeated doses of beta-2 agonists containing edetate disodium. Mayo Clin Proc 75:285-287, 2000.
13. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma N Engl J Med 327:1420-1425, 1992.
14. Salpeter SR, Ormison TM, and Salpeter EE. Meta-anlaysis: Respiratory tolerance to regular β-2-agonist use in patients with asthma. Ann Intern Med 140:802-813, 2004.
15. Hancox RJ, Subbaro P, Kamada D, et al. Beta-2 agonist tolerance and exercise-induced bronchospasm. Am J Resp Crit Care Med 165:1068-1070, 2002.
16. Yates DH, Wordsell M, and Barnes PJ. Effect of regular Salmeterol treatment on albuterol-induced bronchoprotection in mild asthma. Am J Respir Crit Care Med 156:998-991, 1997.
17. Haney S, and Hancox RJ. Tolerance to broncgodialtion during treatment with long-acting beta-agonists, a randomized controlled trial. Respir Res 6:107-114, 2005.
18. Nelson HS, Berkowitz RB, Tinkelman DA, et al. Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. Am J Respir Crit Care Med 159:1556-1561, 1999.
19. Korosec M, Novak RD, Myers E, et al. Salmeterol does not compromise the bronchodilator response to during acute episodes of asthma Am J Med 107:209-213, 1999.
20. Tan KS, Grove A, Mclean PA, et al. Systemic corticosteroidrapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 156:28-35, 1997.
21. Ellul-Micallef R, and Fenech FF. Efffect of intravenous prednisolone in asthamtics with diminished adrenergic responsiveness. Lancet 2:1269-1270, 1975.
22. Giannini D, Bacci E, Federico L, et al. Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of Salmeterol on allergen challenge. Chest 115:629-634, 1999.
23. Rees J. Beta2 agonists and asthma, still the mainstay of symptomatic treatment. BMJ 302:1167-1168, 1991.
24. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2 agonist monotherapy vs. continued therapy with inhaled corticosteroids in patients with persistent asthma. JAMA 285:2583-2893, 2001.
25. Pauwels R, Eliraz A, Pruzinec R, et al. Effect of inhaled formoteroland budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therapy (FACET). N Engl J Med 338:1405-1411, 1998.
26. Wallin A, Sue-Chu M, Bjermer L, et al. Effect of inhaled fluticasone with and without Salmeterol on airway inflammation in asthma. J Allergy Clin Immunol 112:72-78, 2003.
27. Li X, Ward C, Thien F, et al. An anti-inflammatory effect of Salmeterol, a long-acting beta2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 160:1493-1499, 1999.
28. Ni Chroinin M, Greenstone IR, and Ducharme FM. Addition of long acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid naïve adults. Cochrane Database Syst Rev Art CD005307, 2005.
29. Ni Chroinin M, Greenstone IR, Danish A, et al, Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with asthma. Cochrane Database Syst Rev Art CD0005535, 2005.
30. Greenstone IR, Ni Chronin MI, Mass V, et al. Comparison of inhaled long-acting beta-2 agonists versus higher doses of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev Art CD0005533, 2005.
31. Matz J, Emmett A, Rickard K, et al. Addition of Salmeterol to low dose fluticasone versus higher dose fluticasone: An analysis of asthma exacerbations. J Allergy Clin Immunol 112: 29-36, 2001.
32. Crim C, Yancy S, Prillaman B, et al. Retrospective review of studies show that subjects receiving Salmeterol plus an ICS have fewer serious asthma exacerbations versus an ICS alone. Poster 108 ACAAI November 2006.
33. Ducharme FM, Lasserson TJ, and Cates CJ. Long-acting beta2-agonists versus lanti-leukotrienes as add on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev Art CD0003137.
34. Davis B, Brooks G, and Devoy M. The efficacy and safety of Salmeterol compared to theophylline: A meta-analysis of nine controlled studies. Respir Med 92:256-260, 1998.
35. Stempel DA, Stoloff SW, Caranza Rosenzweig JR, et al. Adherence to asthma controller medication regimens. Respir Med 99:1263-1267, 2005.
36. Busse W, Koenig SM, Oppenheimer J, et al. Steroid sparing effects of fluticasone propionate 100 μg and Salmeterol 50 μg administered in a single product in patients previously controlled with fluticasone propionate 250 μg twice daily. J Allergy Clin Immunol 111:57-65, 2003.
37. O'Byrne P, Bisgard H, Godard PP, et al. Budesonide/Formoterol combination therapy as both maintenance and Reliever medication in asthma. Am J Respir Crit Care Med 171:129-136, 2004.
38. The American Lung Association Clinical Research Centers. Randomized comparisons of strategies for reducing treatment in mild persistent asthma. N Engl J Med 356:2027-2039, 2007.
39. Papi A, Canonica G, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 356:2040-2052, 2007.
40. Beier J, Chanez P, Martinet JB, et al. Safety, tolerability, and efficacy of indacaterol, a novel once daily beta(2)-agonist in patients with COPD. Pulm Pharmacol Ther (Epub September 30, 2006).
41. Kottakis I, Nandeui A, Raptis H, et al. Comparison of the efficacy and safety of 5 different doses of the very long acting beta-2 agonists carmoterol. Eur Respir J 50:666, 2006.
42. van Norrd JA, Aumann JL, Janssens E, et al. Efffects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129:509-517, 2006.